BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 18712181)

  • 1. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
    Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
    In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging.
    Mulligan M; Chirindel A; Karchevsky M
    Cancer Invest; 2011 Jun; 29(5):370-6. PubMed ID: 21599514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
    Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
    World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
    Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
    Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
    Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
    Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
    Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
    Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of FDG PET in the assessment of patients with multiple myeloma.
    Bredella MA; Steinbach L; Caputo G; Segall G; Hawkins R
    AJR Am J Roentgenol; 2005 Apr; 184(4):1199-204. PubMed ID: 15788594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
    Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
    Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging in multiple myeloma.
    Delorme S; Baur-Melnyk A
    Recent Results Cancer Res; 2011; 183():133-47. PubMed ID: 21509684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
    Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body (18)F-FDG PET identifies high-risk myeloma.
    Durie BG; Waxman AD; D'Agnolo A; Williams CM
    J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma.
    Breyer RJ; Mulligan ME; Smith SE; Line BR; Badros AZ
    Skeletal Radiol; 2006 Sep; 35(9):632-40. PubMed ID: 16758246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: Solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature.
    Chua SC; O'Connor SR; Wong WL; Ganatra RH
    Br J Radiol; 2008 Apr; 81(964):e110-4. PubMed ID: 18344267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance.
    Adam Z; Bolcak K; Stanicek J; Buchler T; Pour L; Krejci M; Prasek J; Neubauer J; Vorlicek J; Hajek R
    Neoplasma; 2007; 54(6):536-40. PubMed ID: 17949238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.
    Fouquet G; Guidez S; Herbaux C; Van de Wyngaert Z; Bonnet S; Beauvais D; Demarquette H; Adib S; Hivert B; Wemeau M; Berthon C; Terriou L; Coiteux V; Macro M; Decaux O; Facon T; Huglo D; Leleu X
    Clin Cancer Res; 2014 Jun; 20(12):3254-60. PubMed ID: 24714772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin D-lambda type multiple myeloma presenting with FDG-PET/CT negative bone marrow involvement.
    Machida H; Shinohara T; Hino H; Yoshida M; Hatakeyama N; Okano Y; Inayama M; Hosokawa E; Abe S; Naruse K; Iwahara Y; Ogushi F
    Intern Med; 2011; 50(14):1483-7. PubMed ID: 21757834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.